Granisetron Sigillata (Granisetron)

Granisetron Sigillata is indicated for the prevention and treatment of nausea and vomiting associated with several medical procedures.

• Prevention of chemotherapy‑induced nausea and vomiting (CINV).
• Prevention of radiotherapy‑induced nausea and vomiting (RINV).
• Prevention of postoperative nausea and vomiting (PONV) following surgery.
• Adjunct therapy for nausea related to other emetogenic stimuli when other measures are insufficient.
• Use in patients who require a selective 5‑HT3 antagonist with oral dosing convenience.

Granisetron Sigillata may cause side effects; they are categorized by frequency and severity.

Common

• Headache.
• Constipation or mild abdominal discomfort.
• Fatigue or drowsiness.
• Dizziness or light‑headed feeling.

Serious

• Severe allergic reaction such as rash, itching, swelling, or difficulty breathing.
• Cardiac arrhythmia or prolonged QT interval.
• Persistent severe constipation or intestinal blockage.
• Signs of serotonin syndrome when combined with serotonergic agents.

When prescribing Granisetron Sigillata, clinicians should consider several precautionary measures to ensure safe use.

• Assess patient history for hypersensitivity to granisetron or other 5‑HT3 antagonists.
• Use caution in patients with known cardiac conduction disorders or prolonged QT interval.
• Evaluate renal or hepatic impairment, as dose adjustment may be required.
• Monitor for signs of constipation, especially in patients with gastrointestinal motility disorders.
• Discuss pregnancy and breastfeeding status; safety data are limited.
• Review concomitant use of other antiemetics to avoid overlapping effects.

Granisetron Sigillata can interact with other medications; some combinations should be avoided while others require careful monitoring.

Avoid

• Other serotonergic drugs (e.g., SSRIs, SNRIs, tramadol) that may increase risk of serotonin syndrome.
• Medications known to prolong the QT interval (e.g., certain antiarrhythmics, macrolide antibiotics).
• Strong CYP3A4 inhibitors if the product formulation relies on this pathway for metabolism.

Use with caution

• CYP3A4 inducers (e.g., rifampin, carbamazepine) which may reduce granisetron exposure.
• Other antiemetics that act on different receptors, to avoid additive central nervous system effects.
• Diuretics or laxatives, as they may exacerbate constipation when combined with granisetron.